As the quest to find the vaccine of coronavirus proceeds, more and more pharmaceutical companies are coming forward to provide affordable vaccines. To date, at least two pharmaceutical companies who are funded millions by the US government have claimed not to take profit from the vaccine or provide a singular rate around the globe, if the vaccines are proven to cure coronavirus.
In the United States of America, we have seen the most tragic reports of coronavirus patients. The US has invested more than $2.3 billion in the efforts to find the vaccine and treat American citizens. The initiative led by the US coronavirus task force has grilled five leading pharmaceutical companies that are on the verge of developing the vaccine. Namely, AstraZeneca, Johnson & Johnson, Merck, Moderna, and Pfizer.
AstraZeneca claimed to provide 2 billion doses of vaccine, excluding the profit margins of the company. On Monday, AstraZeneca, a British-Swedish company, signed an agreement with the US to provide and supply vaccines to various parts of the United States and other nations.
Johnson & Johnson is another pharmaceutical company that has claimed to provide a single rate vaccine all over the globe. They claim to deliver the vaccine affordable rate and under the tag of emergency pandemic use. Moreover, the company has nearly been funded 500 million dollars from Operation Warp to speed up the development of vaccines.
A US-based pharmaceutical company, Merck, is currently working with two possible vaccine candidates. The Company’s Executive Vice President and Chief Patient officer claims to work with the company to manufacture and supply the vaccines of other pharmaceutical companies if need be. However, the long track record of the company is splendid and filled with great deeds in providing excellent resulting vaccines.
Moreover, Moderna and Pfizer have their possible vaccine candidates. Moderna is funded approximately $536 million to speed up the process of vaccine development by Operation Warp Speed. On the other hand, Pfizer claims to have the investment to build and supply their coronavirus vaccine. The estimated amount by the company is around one billion dollars.